Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9613-9622
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Comparison or stratum | OR (95%CI) | P value |
Age | 1.00 (0.96-1.04) | 0.904 |
Genotype (1 vs 6) | 0.74 (0.30-1.84) | 0.433 |
Genotype (3 vs 6) | 1.33 (0.58-3.05) | 0.433 |
High pretreatment HCV RNA (≥ 800000 IU/mL) | 0.42 (0.19-0.92) | 0.029 |
High pretreatment albumin (≥ 3.5 g/dL) | 2.63 (1.11-6.22) | 0.028 |
High pretreatment platelet (≥ 150000/mm3) | 1.00 (0.45-2.25) | 0.992 |
Liver fibrosis (F3-4 vs F ≤ 2) | 0.19 (0.08-0.48) | < 0.001 |
Sex (female vs male) | 0.57 (0.28-1.16) | 0.120 |
Treatment duration (48 wk vs 24 wk)1 | 2.05 (0.42-9.92) | 0.371 |
- Citation: Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622
- URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9613.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9613